Farmakokinetiske undersøgelser har indikeret, at en stigning i blodniveauet primært skyldes den øgede, orale biotilgængelighed af tacrolimus grundet hæmning af gastrointestinal metabolisme.
Pharmacokinetics studies have indicated that the increase in blood levels is mainly a result of increase in oral bioavailability of tacrolimus owing to the inhibition of gastrointestinal metabolism.